Nanoengineering Apolipoprotein A1‐Based Immunotherapeutics

In the slipstream of targeting adaptive immune system, innate immunotherapy strategies are being developed. this context, technologies based on natural carrier vehicles that inherently interact with increasingly considered. Immunoregulatory nanotherapeutics apolipoprotein A1 (apoA1) discussed here. This protein is a helical, amphipathic macromolecule and main constituent high-density lipoprotein. capacity, apoA1 interacts specifically cells, such as monocytes macrophages, to collect transport lipophilic molecules throughout body. Exactly these unique features make compelling elementary biocompatible self-assembled nanotherapeutics. Such apoA1-based (A1-nanotherapeutics) can be engineered functionalized induce or mitigate an response orchestrate through antigen delivery dendritic cells. The authors first discuss apoA1's properties how exploited generate libraries A1-nanotherapeutics using advanced manufacturing approaches microfluidics continuous flow methods. Using high-throughput in vitro screening methods vivo imaging identify promising formulations then recommend. Finally, three distinct proposed effectively treat variety diseases—including cancer, infection, cardiovascular disease—and promote allograft survival transplantation.